A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

The primary objective of this study is to evaluate the efficacy and safety of **ABP 234** in comparison to **Keytruda® (Pembrolizumab)** in patients with **Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer**. This comparison is clinically relevant as it aims to determine whether ABP 234 can provide a therapeutic alternative to the established treatment with Keytruda®, potentially offering different efficacy or safety profiles that could benefit patient outcomes.

The clinical trial involves a total of **652 participants** diagnosed with **Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer**. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, but they are likely to be individuals who meet the criteria for having the specified medical condition. Lifestyle considerations such as diet, physical activity, or habits are not detailed in the available data. The selection process for the trial population is not explicitly described, and no specific inclusion or exclusion criteria are provided by the sponsor.

The clinical trial is designed to evaluate the efficacy and safety of ABP 234 compared to **Pembrolizumab** in patients with **Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer**. This study is structured as a randomized, double-blind, controlled trial, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thus minimizing bias. The trial is set to commence recruitment on July 31, 2024, and is projected to conclude by August 31, 2028, encompassing a total duration of approximately four years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either ABP 234 or Pembrolizumab. Regular follow-up visits will be scheduled to monitor the participants' health status, treatment adherence, and any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The end-of-study visit will mark the completion of the trial for each participant, during which final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement in the trial is contingent upon the individual's response to treatment and overall health status, with the possibility of early termination if significant adverse effects occur or if the participant withdraws consent. The trial's design and procedures are meticulously crafted to ensure the collection of robust and reliable data, contributing to the understanding of treatment efficacy and safety in this patient population.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is July 31, 2024, with an anticipated end date of August 31, 2028. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials may involve preliminary assessments of efficacy through various measures, potentially including biomarker levels or symptom improvement scores. The methods for measuring, collecting, and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes. The trial's duration and phase suggest a focus on initial efficacy signals alongside safety evaluations.